Application and Development of Computational Methods for Ligand-Based Virtual Screening

The detection of novel active compounds that are able to modulate the biological function of a target is the primary goal of drug discovery. Different screening methods are available to identify hit compounds having the desired bioactivity in a large collection of molecules. As a computational method, virtual screening (VS) is used to search compound libraries in silico and identify those compounds that are likely to exhibit a specific activity. Ligand-based virtual screening (LBVS) is a subdiscipline that uses the information of one or more known active compounds in order to identify new hit compounds. Different LBVS methods exist, e.g. similarity searching and support vector machines (SVMs). In order to enable the application of these computational approaches, compounds have to be described numerically. Fingerprints derived from the two-dimensional compound structure, called 2D fingerprints, are among the most popular molecular descriptors available. This thesis covers the usage of 2D fingerprints in the context of LBVS. The first part focuses on a detailed analysis of 2D fingerprints. Their performance range against a wide range of pharmaceutical targets is globally estimated through fingerprint-based similarity searching. Additionally, mechanisms by which fingerprints are capable of detecting structurally diverse active compounds are identified. For this purpose, two different feature selection methods are applied to find those fingerprint features that are most relevant for the active compounds and distinguish them from other compounds. Then, 2D fingerprints are used in SVM calculations. The SVM methodology provides several opportunities to include additional information about the compounds in order to direct LBVS search calculations. In a first step, a variant of the SVM approach is applied to the multi-class prediction problem involving compounds that are active against several related targets. SVM linear combination is used to recover compounds with desired activity profiles and deprioritize compounds with other activities. Then, the SVM methodology is adopted for potency-directed VS. Compound potency is incorporated into the SVM approach through potencyoriented SVM linear combination and kernel function design to direct search calculations to the preferential detection of potent hit compounds. Next, SVM calculations are applied to address an intrinsic limitation of similarity-based methods, i.e., the presence of similar compounds having large differences in their potency. An especially designed SVM approach is introduced to predict compound pairs forming such activity cliffs. Finally, the impact of different training sets on the recall performance of SVM-based VS is analyzed and caveats are identified

Quantitative Methods in System-Based Drug Discovery

Modern pharmaceutical industries have faced significant challenges to deliver safe and effective medicines because of significant toxicity and severe side effects of discovered drugs. On the other hand, recent developments and advances in system-based pharmacology aim to address these challenges. In this chapter, we provide an overview of quantitative methods for system-based drug discovery. System-based drug discovery integrates chemical, molecular, and systematic information and applies this knowledge to the designing of small molecules with controlled toxicity and minimized side effects. First, we discuss current approaches for drug discovery and outline their advantages and disadvantages. Next, we introduce basic concepts of systems pharmacology with an emphasis on ligand-based drug discovery and target identification. This is followed by a discussion on structure-based drug design and statistical tools for pharmaceutical research. Finally, we provide an overview of future directions in systems pharmacology that will guide further developments

Rational methods for the selection of diverse screening compounds.

Traditionally a pursuit of large pharmaceutical companies, high-throughput screening assays are becoming increasingly common within academic and government laboratories. This shift has been instrumental in enabling projects that have not been commercially viable, such as chemical probe discovery and screening against high-risk targets. Once an assay has been prepared and validated, it must be fed with screening compounds. Crafting a successful collection of small molecules for screening poses a significant challenge. An optimized collection will minimize false positives while maximizing hit rates of compounds that are amenable to lead generation and optimization. Without due consideration of the relevant protein targets and the downstream screening assays, compound filtering and selection can fail to explore the great extent of chemical diversity and eschew valuable novelty. Herein, we discuss the different factors to be considered and methods that may be employed when assembling a structurally diverse compound collection for screening. Rational methods for selecting diverse chemical libraries are essential for their effective use in high-throughput screens.We are grateful for financial support from the MRC, Wellcome Trust, CRUK, EPSRC, BBSRC and Newman Trust.This is the author accepted manuscript. The final version is available from American Chemical Society via http://dx.doi.org/10.1021/cb100420

Computer-aided display control Final report

Human composition and modification of computer driven cathode ray tube displa

Study of ligand-based virtual screening tools in computer-aided drug design

Virtual screening is a central technique in drug discovery today. Millions of molecules can be tested in silico with the aim to only select the most promising and test them experimentally. The topic of this thesis is ligand-based virtual screening tools which take existing active molecules as starting point for finding new drug candidates. One goal of this thesis was to build a model that gives the probability that two molecules are biologically similar as function of one or more chemical similarity scores. Another important goal was to evaluate how well different ligand-based virtual screening tools are able to distinguish active molecules from inactives. One more criterion set for the virtual screening tools was their applicability in scaffold-hopping, i.e. finding new active chemotypes. In the first part of the work, a link was defined between the abstract chemical similarity score given by a screening tool and the probability that the two molecules are biologically similar. These results help to decide objectively which virtual screening hits to test experimentally. The work also resulted in a new type of data fusion method when using two or more tools. In the second part, five ligand-based virtual screening tools were evaluated and their performance was found to be generally poor. Three reasons for this were proposed: false negatives in the benchmark sets, active molecules that do not share the binding mode, and activity cliffs. In the third part of the study, a novel visualization and quantification method is presented for evaluation of the scaffold-hopping ability of virtual screening tools.Siirretty Doriast

The Goldstone solar system radar: A science instrument for planetary research

The Goldstone Solar System Radar (GSSR) station at NASA's Deep Space Communications Complex in California's Mojave Desert is described. A short chronological account of the GSSR's technical development and scientific discoveries is given. This is followed by a basic discussion of how information is derived from the radar echo and how the raw information can be used to increase understanding of the solar system. A moderately detailed description of the radar system is given, and the engineering performance of the radar is discussed. The operating characteristics of the Arcibo Observatory in Puerto Rico are briefly described and compared with those of the GSSR. Planned and in-process improvements to the existing radar, as well as the performance of a hypothetical 128-m diameter antenna radar station, are described. A comprehensive bibliography of referred scientific and engineering articles presenting results that depended on data gathered by the instrument is provided

Next generation 3D pharmacophore modeling

3D pharmacophore models are three‐dimensional ensembles of chemically defined interactions of a ligand in its bioactive conformation. They represent an elegant way to decipher chemically encoded ligand information and have therefore become a valuable tool in drug design. In this review, we provide an overview on the basic concept of this method and summarize key studies for applying 3D pharmacophore models in virtual screening and mechanistic studies for protein functionality. Moreover, we discuss recent developments in the field. The combination of 3D pharmacophore models with molecular dynamics simulations could be a quantum leap forward since these approaches consider macromolecule–ligand interactions as dynamic and therefore show a physiologically relevant interaction pattern. Other trends include the efficient usage of 3D pharmacophore information in machine learning and artificial intelligence applications or freely accessible web servers for 3D pharmacophore modeling. The recent developments show that 3D pharmacophore modeling is a vibrant field with various applications in drug discovery and beyond

Shaping the interaction landscape of bioactive molecules

Motivation: Most bioactive molecules perform their action by interacting with proteins or other macromolecules. However, for a significant fraction of them, the primary target remains unknown. In addition, the majority of bioactive molecules have more than one target, many of which are poorly characterized. Computational predictions of bioactive molecule targets based on similarity with known ligands are powerful to narrow down the number of potential targets and to rationalize side effects of known molecules. Results: Using a reference set of 224 412 molecules active on 1700 human proteins, we show that accurate target prediction can be achieved by combining different measures of chemical similarity based on both chemical structure and molecular shape. Our results indicate that the combined approach is especially efficient when no ligand with the same scaffold or from the same chemical series has yet been discovered. We also observe that different combinations of similarity measures are optimal for different molecular properties, such as the number of heavy atoms. This further highlights the importance of considering different classes of similarity measures between new molecules and known ligands to accurately predict their targets. Contact: [email protected] or [email protected] Supplementary information: Supplementary data are available at Bioinformatics onlin